Update of combined therapies with docetaxel for hormone-independent prostate cancer.
- Author:
Tian-Qing LI
1
;
Jian-Song WANG
Author Information
1. Department of Urology, Yunnan Urology Research Laboratory, the Second Hospital Affiliated to Kunming Medical College, Kunming, Yunnan 650101, China. libing7929@sina.com
- Publication Type:Journal Article
- MeSH:
Angiogenesis Inhibitors;
therapeutic use;
Antineoplastic Agents;
therapeutic use;
Biological Products;
therapeutic use;
Combined Modality Therapy;
Drug Therapy, Combination;
Humans;
Male;
Prostatic Neoplasms;
drug therapy;
Taxoids;
therapeutic use;
Vaccines;
therapeutic use
- From:
National Journal of Andrology
2008;14(3):264-267
- CountryChina
- Language:Chinese
-
Abstract:
Hormone-independent prostate cancer (HIPC) is the end stage of prostate cancer, with a short median survival of 9-18 months for the patients. Two large phase III studies have demonstrated a survival advantage of docetaxel chemotherapy in HIPC patients. New combined protocols have been developed with promising results. These protocols propose a combination with docetaxel, chemotherapy, antiangiogenic agents, vaccine and biological drugs. This review focuses the progress achieved the combined therapies for HIPC.
